Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery

首圖

「Over 30 companies and academic institutions globally have licensed our transgenic mouse platforms for their fully human monoclonal antibody discovery, with several programs at IND-ready stage, and......